

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Finnish Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024094
Article Type:	Protocol
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	<p>Kauppila, Joonas; Karolinska Institutet Department of Molecular Medicine and Surgery, ; Oulun Yliopisto Laaketieteellisen tiedekunta, Cancer and Translational Medicine Research Unit</p> <p>Ohtonen, Pasi; Pohjois-Pohjanmaan Sairaanhoidopiiri, Department of Surgery</p> <p>Karttunen, Tuomo; Oulu University Hospital and University of Oulu, Medical Research Center</p> <p>Kokkola, Arto; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of Surgery</p> <p>Laine, Simo; Varsinais-Suomen Sairaanhoidopiirin Kuntayhtymä, Division of Digestive Surgery and Urology</p> <p>Rantanen, Tuomo; Kuopion yliopistollinen sairaala, Department of Surgery; Etelä-Pohjanmaan keskussairaala, Department of Surgery</p> <p>Ristimäki, Ari; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of Pathology</p> <p>Räsänen, Jari; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of General Thoracic and Oesophageal Surgery</p> <p>Saarnio, Juha; Pohjois-Pohjanmaan Sairaanhoidopiiri, Department of Surgery</p> <p>Sihvo, Eero; Keski Suomen Sairaanhoidopiiri, Department of Surgery</p> <p>Toikkanen, Vesa; Tampereen yliopistollinen sairaala, Department of Cardiothoracic Surgery, Heart Center</p> <p>Tyrväinen, Tuula; Tampereen yliopistollinen sairaala, Department of Gastroenterology and Alimentary Tract Surgery</p>
Keywords:	Oesophageal disease < GASTROENTEROLOGY, Gastrointestinal tumours < GASTROENTEROLOGY, Thoracic surgery < SURGERY, Surgical pathology < PATHOLOGY, Gastrointestinal tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **The Finnish Esophago-Gastric Cancer Cohort (FINEGO) for studying**
4
5 **outcomes after oesophageal and gastric cancer surgery: a protocol for a**
6
7 **retrospective, population-based, nationwide cohort study in Finland**
8
9

10
11
12
13
14 **Authors:** Joonas H. Kauppila^{1,2}, Pasi Ohtonen³, Tuomo J. Karttunen⁴, Arto Kokkola⁵, Simo
15
16 Laine⁶, Tuomo Rantanen⁷, Ari Ristimäki⁸, Jari V. Räsänen⁹, Juha Saarnio³, Eero Sihvo¹⁰,
17
18 Vesa Toikkanen¹¹, Tuula Tyrväinen¹²
19
20
21
22
23

24 **Affiliations:**

25
26 ¹Cancer and Translational Research Unit, Medical Research Center Oulu, Oulu University
27
28 Hospital and University of Oulu, Oulu, Finland

29
30 ²Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska
31
32 Institutet and Karolinska University Hospital, Stockholm, Sweden;

33
34 ³Department of Surgery, Oulu University Hospital, Oulu, Finland

35
36 ⁴Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland;

37
38 ⁵Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki,
39
40 Finland;

41
42 ⁶The Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland;

43
44 ⁷Department of Surgery, University of Eastern Finland and Kuopio University Hospital,
45
46 Finland;

47
48 ⁸Department of Pathology and HUSLAB, University of Helsinki and Helsinki University
49
50 Hospital, Helsinki, Finland

51
52 ⁹Department of General Thoracic and Oesophageal Surgery, Heart and Lung Centre,
53
54
55
56
57
58
59
60

1
2
3 University of Helsinki and Helsinki University Hospital, Helsinki, Finland;

4
5 ¹⁰Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland;

6
7 ¹¹Department of Cardiothoracic Surgery, Heart Center, Tampere University Hospital and
8
9 University of Tampere, Tampere, Finland;

10
11 ¹²Department of Gastroenterology and Alimentary Tract Surgery , Tampere University
12
13 Hospital, Tampere, Finland;

14
15
16
17
18
19 **Corresponding author:** Joonas H. Kauppila, Cancer and Translational Research Unit, MRC
20
21 Oulu, Oulu University Hospital and University of Oulu, P.O. Box 5000, 90014 Oulu, Finland
22
23 and Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery,
24
25 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Email:
26
27 Joonas.kauppila@oulu.fi
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

Surgery for oesophageal and gastric cancers is associated with high morbidity, mortality and poor quality of life postoperatively. The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) will be established with the aim of identifying factors that could contribute to improved outcomes in oesophago-gastric cancer.

Methods and analysis

All oesophageal and gastric cancer patients diagnosed in Finland between 1987 and 2015 will be identified from the Finnish national registries. The Finnish Cancer Registry and Finnish Patient Registry will be used to identify patients that fulfill the inclusion criteria for the study: 1) Diagnosis of oesophageal, gastroesophageal junction, or gastric cancer, 2) any major surgery for the diagnosed cancer and 3) age of 18 or over at the time of diagnosis. Clinical variables and complication information will be retrieved in extensive data collection from the medical records of the relevant Finnish hospitals, and complete follow-up for vital status from Statistics Finland. Primary endpoint is overall all-cause mortality, and secondary endpoints include complications, reoperations, medication use and sick leaves. Sub-studies will be implemented within the cohort to investigate specific populations undergoing oesophageal and gastric cancer surgery. The initial estimated sample size is 1800 patients with surgically treated oesophageal cancer and 7500 patients with surgically treated gastric cancer.

Ethics and dissemination

The study has been approved by the Ethical Committee in Northern Ostrobothnia, Finland and The National Institute for Health and Welfare, Finland. Study findings will be disseminated via presentations at conferences and publications in peer-reviewed journals.

Article Summary

Strengths and limitations of this study:

- The main strength of the study is the population-based design with complete and accurate ascertainment and follow-up of all patients diagnosed with oesophageal or gastric cancer in Finland, counteracting selection bias.
- The inclusion of multiple potential confounding factors from the registries and patient records allows accurate analysis of a variety of exposures and end points.
- The sample size will be large enough to enable robust survival and regression analyses in smaller sub-groups of patients.
- The main limitations of the study are the exclusion of patients not undergoing surgery and information lag of up to two years.

Word count: 2,095

Funding statement: This work is supported by research grants from the Sigrid Jusélius Foundation (Sigrid Juséliuksen Säätiö), The Finnish Cancer Foundation (Syöpäsäätiö) and Orion Research Foundation (Orionin Tutkimussäätiö). The funding sources have no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the study protocol for publication.

Competing interests statement: The authors state no potential competing interests.

Author contributions:

1
2
3 The authors' contributions in the study were the following: JHK initiated the collaborative
4 project, developed the study idea and data collection tools, obtained permissions and funding
5 and drafted the study protocol. PO was involved in the statistical design, made substantial
6 revisions to the protocol and was involved in the original concept, study design and
7 implementation. All authors made substantial revisions to the protocol and were involved in
8 the original concept, study design and implementation. JHK is the guarantor.
9
10
11
12
13
14
15
16
17

18 **Data sharing statement:**

19
20 We are willing to share anonymized data after the completion of the data collection upon
21 request. Sharing the data will require ethical approval by the relevant committee, as well as
22 approvals from the governmental agencies and local entities maintaining the relevant data.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Gastric cancer is the third-, and oesophageal cancer the sixth leading cause of cancer death worldwide.¹ The incidence of oesophageal adenocarcinoma is increasing, while that of oesophageal squamous cell carcinoma and gastric cancer is decreasing in Finland,² similar to other Western countries.³ The incidence of gastric cancer is slowly decreasing in majority of the countries across the globe.⁴ However, both cancers are characterised by poor survival even after curatively intended surgery,^{5,6} and a “textbook outcome” may be achieved in less than half of the patients undergoing oesophago-gastric cancer surgery.⁷ Studies on sick leaves,⁸ or postoperative use of opioids as an outcome after oesophageal and gastric cancer surgery are lacking, while these are important outcomes for the patients. It has been shown that sick leaves affect for example job retention in cancer patients.⁹

Randomized trials in oesophageal and gastric cancer have provided quality evidence that neoadjuvant - and adjuvant therapies increase survival¹⁰⁻¹³ and that minimally invasive surgical approaches reduce, or at least do not increase complications.^{14,15} Despite their good internal validity and lack of bias, randomized controlled studies in general have limited external validity and applicability to general population, and thus need to be complemented by quality observational studies to reliably assess the effects of implementation of trial results into practice.¹⁶ Additionally, observational studies can provide evidence on questions that have not, or cannot, be evaluated in randomized trials.¹⁶

In Finland, high-quality registry data on these cancers is readily available.¹⁷ Despite the good availability, the exposure and outcome data in the registries are not detailed enough for surgical research. Because of small population (5,5 million) sparsely populating Finland, the hospital-based cohorts containing detailed information are small, not necessarily generalizable and have potential selection bias. There are no previous coordinated nationwide population-

1
2 based research efforts with detailed clinical data on oesophago-gastric cancer. To overcome
3 these challenges, an extensive retrospective nationwide data collection from the patient
4 medical records is needed. The Finnish National Esophago-Gastric Cancer Cohort (FINEGO)
5 was established to coordinate this effort.
6
7
8
9
10

11 Objectives

12
13
14
15 The overall objective of FINEGO is to reduce mortality and morbidity associated to
16 oesophageal and gastric cancer, and to improve survivorship after oesophageal and gastric
17 cancer diagnosis.
18
19
20

21
22 Among others, the specific aims of the FINEGO are:

- 23 - To establish important baseline data on national and regional trends in oesophageal and
24 gastric cancer in Finland.
- 25
26 - To investigate associations between operational volume and mortality and morbidity
27 outcomes, as well as survivorship in oesophago-gastric cancers.
- 28
29 - To assess the relevance of clinical characteristics and modifiable risk factors in relation to
30 mortality and morbidity outcomes, as well as cancer survivorship.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

A multicenter FINEGO-collaborative has been established to conduct large-scale epidemiological, clinical and clinicopathological studies in oesophago-gastric cancers. The collaborative includes one to two senior consultant upper gastrointestinal or thoracic surgeons as the local principal investigators (PIs) from all centres conducting oesophageal and gastric cancer surgery in Finland, as well as senior consultant oesophago-gastric pathologists and biostatisticians.

Study design

This study is a population-based, nationwide, retrospective cohort study in Finland. The initial study period is from January 1st, 1987 until December 31st, 2015, with follow up until December 31st, 2016. The study period will be expanded every 5 years to keep the cohort updated for the most recent data.

Inclusion and exclusion criteria

The patients fulfilling the following inclusion criteria are included in the study:

- 1) Primary cancer of epithelial origin in the oesophagus, the gastro-oesophageal junction or the stomach
- 2) Patient receives surgical treatment for the cancer (including curative, palliative, or rescue surgery i.e. surgery after curative chemoradiation)
- 3) Age at least or over 18 years during the time of diagnosis

Identification of the study participants

The immutable, 11-digit personal identification number assigned to each resident in the country allows reliable identification and combining the registry data with patient records.¹⁸

The patients will be identified through the Finnish Cancer Registry, and the Finnish Patient Registry. The identification through both registries is done to ensure near 100% completeness on oesophago-gastric cancer diagnosis. The patients undergoing oesophageal or gastric cancer surgery will be identified using the operations codes in the Finnish Patient Registry. The Finnish Patient Registry will provide the hospital names and operation dates, based on which the relevant patient records will be retrieved from the archives of the relevant hospital districts.

Data collection

Registry data will be collected from *The Finnish Cancer Registry*, *The Finnish Patient Registry*, *The Population Register Centre*, *Statistics Finland* and *The Social Insurance Institution (KELA)-registry* (Table 1). The quality of data in these registries is known to be very high,¹⁹⁻²² and reporting to the registries is mandatory by the Finnish Law. These registry data include the identifying information, the variables related to the socio-economy, and will be used to calculate the well-validated Charlson's comorbidity index²³ and annual hospital volumes. *The patient records* of the included patients identified from the registries will be scrutinized using standardized forms for clinical variables including patient characteristics and surgeon, outcome and complication information (Table 1). The scans of the original diagnostic tissue sample slides for the study patients will be retrieved from the respective regional biobanks for assessment and review of the histological parameters (Table 1).

1
2
3 The identifying information of the selected patients from each hospital district will be
4 provided to the respective PIs and administrative personnel for obtaining the patient records
5 data. The obtained registry data, medical and health records data, as well as the digitalized
6 histological samples, will be entered into the study database and pseudonymised using study
7 identifiers after the completion of the data collection. The hard copies of some of the study
8 data will be kept in a safe deposit on the premises of University of Oulu. The identification
9 variables from the registries will be kept in an encrypted and password-protected file with
10 limited access granted to only the main biostatistician and the principal investigator of the
11 project. The pseudonymised cohort without identifying information is available for the
12 members of the collaborative for sub-studies within the framework specified below.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Data management and analysis plan

29
30
31 The data management and analyses in this study will be supervised and conducted by an
32 expert biostatistician (P.O.). After finishing the data collection, a cohort profile will be
33 published. For the cohort profile, number of new yearly cancer cases, and the yearly number
34 of operated cancers will be calculated based on the registry data. The baseline characteristics,
35 i.e. number of patients in each group of selected variables will be reported in tables. Overall
36 all-cause mortality will be reported for each cancer type based on the life table method,²⁴ and
37 depicted using Kaplan-Meier curves.
38
39
40
41
42
43
44
45
46

47 Each of the sub-studies will be planned in the collaborative with a detailed *a priori* study
48 protocol describing the rationale, aims, hypothesis and statistical analysis plan including
49 appropriate methods, potential confounding and biases for the particular research question, as
50 well as the biostatistician involved in the analysis.
51
52
53
54
55
56
57
58
59
60

Sample size

One of the main strengths is the large sample size of the study. It is estimated that at least 6000 oesophageal and 25000 gastric cancer patients will be found in screening during the study period. Of these patients, estimated 30% have been operated for their cancer, yielding estimates of 1800 oesophageal and 7500 gastric cancer patients for the study.

With 1800 oesophageal cancer patients, the estimated power would be >80% to reliably detect weak associations (Hazard ratio [HR] = 1.15), given an equal distribution of patients in the exposure groups. With 7500 gastric cancer patients, the power would be >80 to detect an association at the level HR=1.07.

Permissions and registration

The study has been approved by ethical committee in Northern Ostrobothnia, Finland, as well as The National Institute for Health and Welfare, Finland. Relevant local permissions and registrations are applied by the collaborative.

Individual informed consent will not be sought from the patients whose data are used in this observational study. Obtaining the informed consent has been waived by the Finnish law. The study will be conducted in accordance with the Declaration of Helsinki.

Discussion

Oesophageal and gastric cancers have poor prognosis, even after curative surgery.^{5,6} The present population-based, nationwide retrospective cohort study will provide information on the recent time trends in the treatment of oesophageal and gastric cancer and identify new, and verify previously identified, modifiable factors related to morbidity, mortality and survivorship after oesophageal and gastric cancer surgery.

The strengths of the FINEGO-cohort include its population-based design with complete and accurate ascertainment and follow-up of all patients diagnosed with oesophageal or gastric cancer in Finland, counteracting selection bias. The combined use of registry and patient records data reduces information bias. The inclusion of multiple potential confounding factors from the registries and patient records allows accurate analysis of a variety of exposures and end points. The sample size will large enough to enable robust survival and regression analyses in smaller sub-groups of patients.

There are also limitations in the present study. All patients not undergoing surgery will be excluded, because examining the patient records for all the patients would increase the number of involved hospital districts and primary care centres significantly, reducing the feasibility of the data collection. As a result the few patients treated with endoscopic mucosal resection or endoscopic submucosal dissection will also be excluded. However, these approaches are not widely applied in the treatment of oesophageal or gastric cancer in Finland. Patients undergoing curatively intended or palliative chemo- and/or radiotherapy will also be excluded, reducing the possibilities to study patients with disseminated disease or not eligible for surgery. The cohort is planned to be updated every five years and there is a lag of up to two years, including quality checks and controls, before the registry data is made available for research, preventing the study group from getting the most recent data for

1
2
3 analysis even during the cohort updates. However, this lag will not reduce the relative sample
4
5 size considerably, and the effect on follow-up in person-years is minimal due to high
6
7 mortality rates of the cancers. Furthermore, there are some variables, including smoking
8
9 history and alcohol use, that are not recorded in the registries and cannot be reliably retrieved
10
11 from the patient records, as they are not routinely recorded by the health care personnel in a
12
13 structured way. However, the data quality and missing data will be meticulously checked
14
15 before running the sub-studies, and the missing data will be taken into account by using
16
17 multiple imputation methods in the analyses to reduce bias from missing data.
18
19

20
21 Taken together, this population-based, nationwide retrospective cohort study will provide new
22
23 evidence regarding various unanswered questions in oesophageal and gastric cancer surgery
24
25 by combining epidemiological and clinical data, as well as complement randomized clinical
26
27 trials by assessing their findings in an unselected population.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol* 2017; 3(4):524-548.
2. Weiderpass E, Pukkala E. Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. *BMC Gastroenterol* 2006; 6:41.
3. Malhotra GK, Yanala U, Ravipati A, et al. Global trends in esophageal cancer. *J Surg Oncol* 2017; 115(5):564-579.
4. Luo G, Zhang Y, Guo P, et al. Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis. *Int J Cancer* 2017; 141(7):1333-1344.
5. Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. *Lancet* 2017.
6. Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. *Lancet* 2016; 388(10060):2654-2664.
7. van der Kaaij RT, de Rooij MV, van Coevorden F, et al. Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery. *Br J Surg* 2018.
8. Endo M, Haruyama Y, Takahashi M, et al. Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors. *J Cancer Surviv* 2016; 10(2):320-9.
9. Veenstra CM, Regenbogen SE, Hawley ST, et al. Association of Paid Sick Leave With Job Retention and Financial Burden Among Working Patients With Colorectal Cancer. *JAMA* 2015; 314(24):2688-90.
10. Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol* 2015; 16(9):1090-1098.
11. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; 355(1):11-20.
12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; 345(10):725-30.
13. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol* 2007; 25(24):3719-25.
14. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012; 379(9829):1887-92.
15. Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg* 2010; 251(3):417-20.
16. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer* 2014; 110(3):551-5.
17. Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: Possibilities and pitfalls when combining Nordic registry data. *Scand J Public Health* 2017; 45(17_suppl):14-19.
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol* 2009; 24(11):659-67.
19. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. *Scand J Public Health* 2012; 40(6):505-15.
20. Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. *Eur J Cancer* 2017; 77:31-39.

- 1
- 2
- 3 21. Lahti RA, Penttila A. The validity of death certificates: routine validation of death certification
- 4 and its effects on mortality statistics. *Forensic Sci Int* 2001; 115(1-2):15-32.
- 5 22. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for
- 6 pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010; 106(2):86-94.
- 7 23. Armitage JN, Van Der Meulen JH. Identifying co-morbidity in surgical patients using
- 8 administrative data with the Royal College of Surgeons Charlson Score. *British Journal of*
- 9 *Surgery* 2010; 97(5):772-781.
- 10 24. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. *J*
- 11 *Chronic Dis* 1958; 8(6):699-712.
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Table 1. Data sources and dataset information

Data Source	Variables
<i>The Finnish Cancer Registry</i>	Personal identification number (age, sex) Diagnosis number Date of cancer diagnosis Tumour stage
<i>The Finnish Patient Registry</i>	Personal identification number (age, sex) Hospital admissions data -Admitting hospital -Dates of admission and discharge -Diagnosis codes -Operations codes
<i>The Population Register Centre</i>	Marital status
<i>Statistics Finland</i>	Education level Date of death Causes of death
<i>KELA registry</i>	Dispensed drugs -Type (ATC-code) -Date dispensed -Amount of dispensed drug Sick leave (start date, end date) Pension information (start date)
<i>Patient records</i>	Tumour stage information Anesthesia information -Type of anaesthesia -ASA classification* Surgery information -Type of surgery -Surgeon volume -Bleeding -Operation duration Complications -According to the ECCG -Clavien-Dindo classification Oncological treatment -Neoadjuvant and adjuvant treatment -Treatment modality -Complications Pathology -Tumour location and stage -Lymph node yield and resection radicality Hospital and ICU stay
<i>Biobanks</i>	Scans of original diagnostic slides

BMJ Open

The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024094.R1
Article Type:	Protocol
Date Submitted by the Author:	10-Oct-2018
Complete List of Authors:	<p>Kauppila, Joonas; Karolinska Institutet Department of Molecular Medicine and Surgery, ; Oulun Yliopisto Laaketieteellisen tiedekunta, Cancer and Translational Medicine Research Unit Ohtonen, Pasi; Pohjois-Pohjanmaan Sairaanhoidopiiri, Department of Surgery Karttunen, Tuomo; Oulu University Hospital and University of Oulu, Medical Research Center Kokkola, Arto; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of Surgery Laine, Simo; Varsinais-Suomen Sairaanhoidopiirin Kuntayhtymä, Division of Digestive Surgery and Urology Rantanen, Tuomo; Kuopion yliopistollinen sairaala, Department of Surgery; Etelä-Pohjanmaan keskussairaala, Department of Surgery Ristimäki, Ari; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of Pathology Räsänen, Jari; Helsingin ja Uudenmaan sairaanhoidopiiri, Department of General Thoracic and Oesophageal Surgery Saarnio, Juha; Pohjois-Pohjanmaan Sairaanhoidopiiri, Department of Surgery Sihvo, Eero; Keski Suomen Sairaanhoidopiiri, Department of Surgery Toikkanen, Vesa; Tampereen yliopistollinen sairaala, Department of Cardiothoracic Surgery, Heart Center Tyrväinen, Tuula; Tampereen yliopistollinen sairaala, Department of Gastroenterology and Alimentary Tract Surgery</p>
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Oncology, Pathology
Keywords:	Oesophageal disease < GASTROENTEROLOGY, Gastrointestinal tumours < GASTROENTEROLOGY, Thoracic surgery < SURGERY, Surgical pathology < PATHOLOGY, Gastrointestinal tumours < ONCOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for**
4
5 **studying outcomes after oesophageal and gastric cancer surgery: a protocol**
6
7 **for a retrospective, population-based, nationwide cohort study in Finland**
8
9

10
11
12
13
14 **Authors:** Joonas H. Kauppila^{1,2}, Pasi Ohtonen³, Tuomo J. Karttunen⁴, Arto Kokkola⁵, Simo
15
16 Laine⁶, Tuomo Rantanen⁷, Ari Ristimäki⁸, Jari V. Räsänen⁹, Juha Saarnio³, Eero Sihvo¹⁰,
17
18 Vesa Toikkanen¹¹, Tuula Tyrväinen¹²
19
20
21
22
23

24 **Affiliations:**

25
26 ¹Cancer and Translational Research Unit, Medical Research Center Oulu, Oulu University
27
28 Hospital and University of Oulu, Oulu, Finland
29

30
31 ²Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska
32
33 Institutet and Karolinska University Hospital, Stockholm, Sweden;
34

35 ³Department of Surgery, Oulu University Hospital, Oulu, Finland
36

37 ⁴Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland;
38

39 ⁵Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki,
40
41 Finland;
42

43 ⁶The Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland;
44

45
46 ⁷Department of Surgery, University of Eastern Finland and Kuopio University Hospital,
47
48 Finland;
49

50 ⁸Department of Pathology and HUSLAB, University of Helsinki and Helsinki University
51
52 Hospital, Helsinki, Finland
53

54 ⁹Department of General Thoracic and Oesophageal Surgery, Heart and Lung Centre,
55
56
57
58
59
60

1
2
3 University of Helsinki and Helsinki University Hospital, Helsinki, Finland;

4
5 ¹⁰Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland;

6
7 ¹¹Department of Cardiothoracic Surgery, Heart Center, Tampere University Hospital and

8
9 University of Tampere, Tampere, Finland;

10
11 ¹²Department of Gastroenterology and Alimentary Tract Surgery , Tampere University

12
13 Hospital, Tampere, Finland;

14
15
16
17
18
19 **Corresponding author:** Joonas H. Kauppila, Cancer and Translational Research Unit, MRC

20
21 Oulu, Oulu University Hospital and University of Oulu, P.O. Box 5000, 90014 Oulu, Finland

22
23 and Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery,

24
25 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Email:

26
27 Joonas.kauppila@oulu.fi

Abstract

Introduction

Surgery for oesophageal and gastric cancers is associated with high morbidity, mortality and poor quality of life postoperatively. The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) has been established with the aim of identifying factors that could contribute to improved outcomes in oesophago-gastric cancer.

Methods and analysis

All oesophageal and gastric cancer patients diagnosed in Finland between 1987 and 2015 will be identified from the Finnish national registries. The Finnish Cancer Registry and Finnish Patient Registry will be used to identify patients that fulfill the inclusion criteria for the study:

1) Diagnosis of oesophageal, gastroesophageal junction, or gastric cancer, 2) any surgical treatment for the diagnosed cancer and 3) age of 18 or over at the time of diagnosis. Clinical variables and complication information will be retrieved in extensive data collection from the medical records of the relevant Finnish hospitals, and complete follow-up for vital status from Statistics Finland. Primary endpoint is overall all-cause mortality, and secondary endpoints include complications, reoperations, medication use and sick leaves. Sub-studies will be implemented within the cohort to investigate specific populations undergoing oesophageal and gastric cancer surgery. The initial estimated sample size is 1800 patients with surgically treated oesophageal cancer and 7500 patients with surgically treated gastric cancer.

Ethics and dissemination

The study has been approved by the Ethical Committee in Northern Ostrobothnia, Finland and The National Institute for Health and Welfare, Finland. Study findings will be disseminated via presentations at conferences and publications in peer-reviewed journals.

Article Summary

Strengths and limitations of this study:

- The main strength of the study is the population-based design with complete and accurate ascertainment and follow-up of all patients diagnosed with oesophageal or gastric cancer in Finland, counteracting selection bias.
- The inclusion of multiple potential confounding factors from the registries and patient records allows accurate analysis of a variety of exposures and end points.
- The sample size will be large enough to enable robust survival and regression analyses in smaller sub-groups of patients.
- The main limitations of the study are the exclusion of patients not undergoing surgery and information lag of up to two years.

Word count: 2,762

Funding statement: This work is supported by research grants from the Sigrid Jusélius Foundation (Sigrid Juséliuksen Säätiö), The Finnish Cancer Foundation (Syöpäsäätiö) and Orion Research Foundation (Orionin Tutkimussäätiö). The funding sources have no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the study protocol for publication.

Competing interests statement: The authors state no potential competing interests.

Author contributions:

1
2
3 JHK developed the study idea, concept and design, initiated the collaborative project,
4 developed data collection tools, obtained permissions and funding, and drafted the study
5 protocol. PO was involved in the statistical design, made substantial revisions to the protocol
6 and was involved in the original concept, study design and implementation. TJK was involved
7 in design and implementation of the study, and revised the protocol. AK was involved in
8 design and implementation of the study, and revised the protocol. SL was involved in design
9 and implementation of the study, and revised the protocol. TR was involved in design and
10 implementation of the study, and revised the protocol. AR was involved in design and
11 implementation of the study, and revised the protocol. JR was involved in design and
12 implementation of the study, and revised the protocol. JS was involved in design and
13 implementation of the study, and revised the protocol. ES was involved in design and
14 implementation of the study, and revised the protocol. VT was involved in design and
15 implementation of the study, and revised the protocol. TT was involved in design and
16 implementation of the study, and revised the protocol. JHK is the guarantor.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 **Data sharing statement:**

36 We are willing to share anonymized data after the completion of the data collection upon
37 request. Sharing the data will require ethical approval by the relevant committee, as well as
38 approvals from the governmental agencies and local entities maintaining the relevant data.

39 Researchers interested in collaboration are welcome to contact Joonas Kauppila
40 (joonas.kauppila@oulu.fi), the principal investigator (PI) of FINEGO, or one of the local PIs.

41 The access to data is currently restricted, but the applications for other researchers can be
42 submitted by the FINEGO investigators to the relevant agencies and entities for approval.

Introduction

Gastric cancer is the third-, and oesophageal cancer the sixth leading cause of cancer death worldwide.¹ The incidence of oesophageal adenocarcinoma is increasing, while that of oesophageal squamous cell carcinoma and gastric cancer is decreasing in Finland,² similar to other Western countries.³ The incidence of gastric cancer is slowly decreasing in majority of the countries across the globe.⁴ However, both cancers are characterised by poor survival even after curatively intended surgery,⁵⁻⁸ and a “textbook outcome” may be achieved in less than half of the patients undergoing oesophago-gastric cancer surgery.⁹ Studies on sick leaves,¹⁰ or postoperative use of opioids as an outcome after oesophageal and gastric cancer surgery are lacking, while these are important outcomes for the patients. It has been shown that sick leaves affect for example job retention in cancer patients.¹¹

Randomized trials in oesophageal and gastric cancer have provided quality evidence that neoadjuvant - and adjuvant therapies increase survival¹²⁻¹⁵ and that minimally invasive surgical approaches reduce, or at least do not increase complications.^{16 17} Despite their good internal validity and lack of bias, randomized controlled studies in general have limited external validity and applicability to general population, and thus need to be complemented by quality observational studies to reliably assess the effects of implementation of trial results into practice.¹⁸ Additionally, observational studies can provide evidence on questions that have not, or cannot, be evaluated in randomized trials.¹⁸

In Finland, high-quality registry data on these cancers is readily available.¹⁹ Despite the good availability, the exposure and outcome data in the registries are not detailed enough for surgical research. Because of small population (5,5 million) sparsely populating Finland, the hospitals are many, and the single-center cohorts containing detailed information are small, not necessarily generalizable and have potential selection bias. There are no previous

1
2
3 coordinated nationwide population-based research efforts with detailed clinical data on
4
5 oesophago-gastric cancer in Finland. To overcome these challenges, an extensive
6
7 retrospective nationwide data collection from the patient medical records is needed. The
8
9 Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established as a researcher-
10
11 led effort to coordinate this retrospective database.
12

13 14 Objectives

15
16
17 The specific objectives of the FINEGO are:

- 18
19
20 - To establish important baseline data on national and regional trends and changes over time
21
22 in oesophageal and gastric cancer surgery, postoperative morbidity and long-term outcomes in
23
24 Finland.
25
- 26
27 - To investigate associations between surgeon and hospital volume and postoperative
28
29 morbidity and mortality in oesophago-gastric cancers.
30
31
- 32
33 - To assess the relevance of clinical characteristics, modifiable risk factors, such as
34
35 preoperative feeding, surgical approach, type of neoadjuvant treatment, or method of
36
37 analgesia in relation to mortality and morbidity outcomes, as well as cancer survivorship, such
38
39 as postoperative medication use in esophago-gastric cancer.
40
41
- 42
43 - To investigate whether histological assessment could be used for prediction of prognosis in
44
45 esophageal and gastric cancer.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

A multicenter FINEGO-collaborative has been established to conduct large-scale epidemiological, clinical and clinicopathological studies in oesophago-gastric cancers. The collaborative includes one to two senior consultant upper gastrointestinal or thoracic surgeons as the local principal investigators (PIs) from all academic centres conducting oesophageal and gastric cancer surgery in Finland, as well as senior consultant oesophago-gastric pathologists and biostatisticians. The participating researchers will sign the needed professional confidentiality consents to be allowed access to patient data obtained from the registries.

Study design

This study is a population-based, nationwide, retrospective cohort study in Finland. The initial study period is from January 1st, 1987 until December 31st, 2015, with follow up until December 31st, 2016. The study period will be expanded every 5 years to keep the cohort updated for the most recent data.

Inclusion and exclusion criteria

The patients fulfilling the following inclusion criteria are included in the study:

- 1) Primary cancer of epithelial origin in the oesophagus, the gastro-oesophageal junction or the stomach
- 2) Patient receives surgical treatment for the cancer, including curative, palliative, rescue surgery i.e. surgery after curative chemoradiation, or endoscopical curative surgery, such as

1
2
3 endoscopic mucosal resection and endoscopic submucosal dissection

4
5 3) Age at least or over 18 years during the time of diagnosis
6
7
8
9

10 Identification of the study participants

11
12
13 The immutable, 11-digit personal identification number assigned to each resident in the
14 country allows reliable identification and combining the registry data with patient records.²⁰
15
16 The patients will be identified through the Finnish Cancer Registry, and the Finnish Patient
17 Registry by searching these registries for cancer diagnoses (Supplementary Table 1) and
18 operation status and operations codes (Supplementary Table 2). The identification through
19 both registries is done to ensure near 100% completeness on oesophago-gastric cancer
20 diagnosis. The patients undergoing oesophageal or gastric cancer surgery will be identified
21 using the operations codes in the Finnish Patient Registry. The Finnish Patient Registry will
22 provide the hospital names and operation dates, based on which the relevant patient records
23 will be retrieved from the archives of the hospitals in all 21 hospital districts in Finland.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Data collection

40
41
42 Registry data will be collected from *The Finnish Cancer Registry*, *The Finnish Patient*
43 *Registry*, *The Population Register Centre*, *Statistics Finland* and *The Social Insurance*
44 *Institution (KELA)-registry* (Table 1). The quality of data in these registries is known to be
45 very high,²¹⁻²⁴ and reporting to the registries is mandatory by the Finnish Law. These registry
46 data include the identifying information, the variables related to the socio-economy, and will
47 be used to calculate the well-validated Charlson's comorbidity index (Supplementary table
48 3)²⁵ and annual hospital volumes. All registry data-derived variables are calculated by a
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 biostatistician. *The patient records* of the included patients identified from the registries will
4
5 be scrutinized by the study nurses and the investigators using standardized forms for clinical
6
7 variables, including patient characteristics and surgeon, outcome and complication
8
9 information (Table 1 and Supplementary Text 1). The clinical variables have been decided on
10
11 by the investigators in the FINEGO group. Key variables, such as those from the operations
12
13 charts will be extracted by one of the investigators, while the nurse extracts information not
14
15 considered prone to errors, such as administrative data and laboratory results. All records and
16
17 the corresponding data collection forms will be scanned and saved for later use. *The*
18
19 *histological samples* will be collected from the biobanks. These original, prospectively
20
21 collected diagnostic slides from the pre-operative gastroscopy and the surgical specimen will
22
23 be sought from the biobanks' archives for the study patients. The sample slides are retrieved
24
25 according to the biobank policies, and scanned and digitized into a picture form for
26
27 assessment and review of the histological parameters and neoadjuvant treatment response
28
29 (Table 1).
30
31

32
33
34 The identifying information of the selected patients from each hospital district will be
35
36 provided to the respective PIs and administrative personnel for obtaining the patient records
37
38 data from the health care entities' archives. The obtained registry data, medical and health
39
40 records data, as well as the digitized histological samples, will be entered into the study
41
42 database and pseudonymised using study identifiers after the completion of the data
43
44 collection. The hard copies of some of the study data will be kept in a safe deposit on the
45
46 premises of University of Oulu. The identification variables from the registries will be kept in
47
48 an encrypted and password-protected file with limited access granted to only the main
49
50 biostatistician and the principal investigator of the project. The pseudonymised cohort without
51
52 identifying information is available for the members of the collaborative for sub-studies
53
54 within the framework specified below.
55
56
57
58
59
60

Data management and analysis plan

The data management and analyses in this study will be supervised and conducted by an expert biostatistician (P.O.). After finishing the data collection, a cohort profile will be published. For the cohort profile, number of new yearly cancer cases, and the yearly number of operated cancers will be calculated based on the registry data. The baseline characteristics, i.e. number of patients in each group of selected variables will be reported in tables. Overall all-cause mortality will be reported for each cancer type based on the life table method,²⁶ and depicted using Kaplan-Meier curves.

Each of the sub-studies will be planned in the collaborative with a detailed *a priori* study protocol describing the rationale, aims, hypothesis and statistical analysis plan including appropriate methods, potential confounding and biases for the particular research question, as well as the biostatistician involved in the analysis.

Data quality assessment

The data quality in the registries will be checked through comparing the collected clinical data against the data, namely type of surgery, and tumor stage obtained from the registries. Internal audit, where a random sample of the patient records of 50 esophageal cancer patients and 50 gastric cancer patients will be re-reviewed by an another investigator, and the differences between the two assessments will be checked against the original data collection. If there are signs of difficulties in the assessment of certain variables or systematic errors, these variables will be audited in more detail. As of now, no external audit is planned, but all study protocols,

1
2 data files, statistical syntax used to obtain the results, and the end-product will be kept for
3
4 further potential audits.
5
6
7
8
9

10 Sample size

11
12
13 One of the main strengths is the large sample size of the study. It is estimated that at least
14
15 6000 oesophageal and 25000 gastric cancer patients will be found in screening during the
16
17 study period. Of these patients, estimated 30% have been operated for their cancer, yielding
18
19 estimates of 1800 oesophageal and 7500 gastric cancer patients for the study.
20
21

22
23 With 1800 oesophageal cancer patients, the estimated power would be >80% to reliably detect
24
25 weak associations (Hazard ratio [HR] = 1.15), given an equal distribution of patients in the
26
27 exposure groups. With 7500 gastric cancer patients, the power would be >80 to detect an
28
29 association at the level HR=1.07.
30
31

32 Permissions and registration

33
34
35 The study has been approved by ethical committee in Northern Ostrobothnia, The National
36
37 Institute for Health and Welfare, Statistics Finland and the Office of the Data Protection
38
39 Ombudsman, Finland. Relevant local permissions and registrations are obtained by the
40
41 collaborative from all the 21 hospital districts, namely the Lapland Hospital district, Länsi-
42
43 Pohja hospital district, Kainuun Social and Health Care Joint Authority, The Hospital district
44
45 of Northern Ostrobothnia, Soite, The Hospital District of South Ostrobothnia, Pirkanmaa
46
47 Hospital District, Kanta-Häme Hospital District, Vaasa Hospital District, Satakunta Hospital
48
49 District, Hospital District of Southwest Finland, Ålands hälso- och sjukvård, Joint Authority
50
51 of the Helsinki and Uusimaa Hospital District, Päijät-Häme Hospital District, Kymenlaakso
52
53
54
55
56
57
58
59
60

1
2
3 Social and Health Services Carea, South Karelia Social and Health Care District (Eksote),
4
5 North Karelia Central Hospital and Honkalampi Centre, East Savo Hospital District, South
6
7 Savo Social and Health Services, Kuopio University Hospital District and The Central
8
9 Finland Hospital District, as well as the relevant Biobanks, namely Auria Biobank, Helsinki
10
11 Biobank, Biobank of Eastern Finland, Central Finland Biobank, Northern Finland Biobank
12
13 Borealis and Finnish Clinical Biobank Tampere.
14
15

16
17 Individual informed consent will not be sought from the patients whose data are used in this
18
19 observational study. Obtaining the informed consent has been waived by the Finnish law. The
20
21 study will be conducted in accordance with the Declaration of Helsinki.
22
23
24
25

26 Patient and public involvement

27
28
29 Patients or public were not involved in the development of the research question and study
30
31 design or conducting the present study.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Oesophageal and gastric cancers have poor prognosis, even after curative surgery.^{5,6} The present population-based, nationwide retrospective cohort study will provide information on the recent time trends in the treatment of oesophageal and gastric cancer and identify new, and verify previously identified, modifiable factors related to morbidity, mortality and survivorship after oesophageal and gastric cancer surgery.

The strengths of the FINEGO-cohort include its population-based design with complete and accurate ascertainment and follow-up of all patients diagnosed with oesophageal or gastric cancer in Finland, counteracting selection bias. The combined use of registry and patient records data reduces information bias. The inclusion of multiple potential confounding factors from the registries and patient records allows accurate analysis of a variety of exposures and end points. The sample size will large enough to enable robust survival and regression analyses in smaller sub-groups of patients. Compared to some global collaboratives, such as the Worldwide Esophageal Cancer Collaboration (WECC)²⁷ or Esophagectomy Complications Consensus Group (ECCG)²⁸, the FINEGO can contribute to the scientific community by producing results in a real-life setting including all patients operated for esophageal and gastric cancers in the country, while the collaboratives typically include a sample of patients operated in high-volume centres. Furthermore, the above mentioned collaboratives include only esophageal cancer, while the present study includes both esophageal and gastric cancer.

There are also limitations in the present study. The retrospective study design is potentially weaker in data quality, compared to a prospective study. However, the retrospective design enables obtaining a large number of patients more quickly than a prospective data collection, and the data quality in the registries the cohort is based on is known to be very high, and the

1
2 manually collected patient records data will be vigorously checked and validated for quality.
3
4 Furthermore, a national quality registry for these patients is going to be established, and the
5
6 prospective clinical data collected in that quality registry can be later used in the updates of
7
8 the FINEGO-cohort to potentially improve the quality of the more recent data. All patients not
9
10 undergoing surgery will be excluded, because examining the patient records for all the
11
12 patients would increase the number of involved health care entities significantly to over 250,
13
14 reducing the feasibility of the data collection. Patients undergoing curatively intended or
15
16 palliative chemo- and/or radiotherapy will be excluded, reducing the possibilities to study
17
18 patients with disseminated disease or not eligible for any type of surgery. The cohort is
19
20 planned to be updated every five years and there is a lag of up to two years, including quality
21
22 checks and controls, before the registry data is made available for research, preventing the
23
24 study group from getting the most recent data for analysis even during the cohort updates.
25
26 However, this lag will not reduce the relative sample size considerably, and the effect on
27
28 follow-up in person-years is minimal due to high mortality rates of the cancers. Furthermore,
29
30 there are some variables, including smoking history and alcohol use, that are not recorded in
31
32 the registries and cannot be reliably retrieved from the patient records, as they are not
33
34 routinely recorded by the health care personnel in a structured way. However, the data quality
35
36 and missing data will be meticulously checked before running the sub-studies, and the
37
38 missing data will be taken into account by using multiple imputation methods in the analyses
39
40 to reduce bias from missing data.
41
42
43
44
45

46 Taken together, this population-based, nationwide retrospective cohort study will provide new
47
48 evidence regarding various unanswered questions in oesophageal and gastric cancer surgery
49
50 by combining epidemiological and clinical data, as well as complement randomized clinical
51
52 trials by assessing their findings in an unselected population.
53
54
55
56
57
58
59
60

References

1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol* 2017;3(4):524-48. doi: 10.1001/jamaoncol.2016.5688
2. Weiderpass E, Pukkala E. Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. *BMC Gastroenterol* 2006;6:41. doi: 10.1186/1471-230X-6-41
3. Malhotra GK, Yanala U, Ravipati A, et al. Global trends in esophageal cancer. *J Surg Oncol* 2017;115(5):564-79. doi: 10.1002/jso.24592 [published Online First: 2017/03/21]
4. Luo G, Zhang Y, Guo P, et al. Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis. *Int J Cancer* 2017;141(7):1333-44. doi: 10.1002/ijc.30835 [published Online First: 2017/06/15]
5. Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. *Lancet* 2017 doi: 10.1016/S0140-6736(17)31462-9
6. Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. *Lancet* 2016;388(10060):2654-64. doi: 10.1016/S0140-6736(16)30354-3
7. Kauppila JH, Mattsson F, Brusselsaers N, et al. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. *BMJ Open* 2018;8(5):e021495. doi: 10.1136/bmjopen-2018-021495 [published Online First: 2018/05/12]
8. Asplund J, Kauppila JH, Mattsson F, et al. Survival Trends in Gastric Adenocarcinoma: A Population-Based Study in Sweden. *Ann Surg Oncol* 2018;25(9):2693-702. doi: 10.1245/s10434-018-6627-y [published Online First: 2018/07/11]
9. van der Kaaij RT, de Rooij MV, van Coevorden F, et al. Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery. *Br J Surg* 2018 doi: 10.1002/bjs.10729 [published Online First: 2018/02/22]
10. Endo M, Haruyama Y, Takahashi M, et al. Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors. *J Cancer Surviv* 2016;10(2):320-9. doi: 10.1007/s11764-015-0478-3 [published Online First: 2015/09/01]
11. Veenstra CM, Regenbogen SE, Hawley ST, et al. Association of Paid Sick Leave With Job Retention and Financial Burden Among Working Patients With Colorectal Cancer. *JAMA* 2015;314(24):2688-90. doi: 10.1001/jama.2015.12383 [published Online First: 2015/12/31]
12. Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol* 2015;16(9):1090-98. doi: 10.1016/S1470-2045(15)00040-6 [published Online First: 2015/08/10]
13. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355(1):11-20. doi: 10.1056/NEJMoa055531 [published Online First: 2006/07/11]
14. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345(10):725-30. doi: 10.1056/NEJMoa010187 [published Online First: 2001/09/08]
15. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol* 2007;25(24):3719-25. doi: 10.1200/JCO.2006.10.4760 [published Online First: 2007/08/21]
16. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012;379(9829):1887-92. doi: 10.1016/S0140-6736(12)60516-9 [published Online First: 2012/05/04]

17. Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg* 2010;251(3):417-20. doi: 10.1097/SLA.0b013e3181cc8f6b [published Online First: 2010/02/18]
18. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer* 2014;110(3):551-5. doi: 10.1038/bjc.2013.725 [published Online First: 2014/02/06]
19. Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: Possibilities and pitfalls when combining Nordic registry data. *Scand J Public Health* 2017;45(17_suppl):14-19. doi: 10.1177/1403494817702336
20. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol* 2009;24(11):659-67. doi: 10.1007/s10654-009-9350-y
21. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. *Scand J Public Health* 2012;40(6):505-15. doi: 10.1177/1403494812456637 [published Online First: 2012/08/18]
22. Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. *Eur J Cancer* 2017;77:31-39. doi: 10.1016/j.ejca.2017.02.017 [published Online First: 2017/03/30]
23. Lahti RA, Penttila A. The validity of death certificates: routine validation of death certification and its effects on mortality statistics. *Forensic Sci Int* 2001;115(1-2):15-32. [published Online First: 2000/11/01]
24. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106(2):86-94. doi: 10.1111/j.1742-7843.2009.00494.x [published Online First: 2009/12/08]
25. Armitage JN, Van Der Meulen JH. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. *Brit J Surg* 2010;97(5):772-81. doi: 10.1002/bjs.6930
26. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. *J Chronic Dis* 1958;8(6):699-712.
27. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. *Dis Esophagus* 2009;22(1):1-8. doi: 10.1111/j.1442-2050.2008.00901.x [published Online First: 2009/02/07]
28. Low DE, Alderson D, Ceconello I, et al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). *Ann Surg* 2015;262(2):286-94. doi: 10.1097/SLA.0000000000001098 [published Online First: 2015/01/22]

Table 1. Data sources and dataset information

Data Source	Variables
<i>The Finnish Cancer Registry</i>	Personal identification number (age, sex) Diagnosis number Date of cancer diagnosis Tumour stage
<i>The Finnish Patient Registry</i>	Personal identification number (age, sex) Hospital admissions data -Admitting hospital -Dates of admission and discharge -Diagnosis codes -Operations codes
<i>The Population Register Centre</i>	Marital status
<i>Statistics Finland</i>	Education level Date of death Causes of death
<i>KELA registry</i>	Dispensed drugs -Type (ATC-code) -Date dispensed -Amount of dispensed drug Sick leave (start date, end date) Pension information (start date)
<i>Patient records</i>	Tumour stage information Anesthesia information -Type of anaesthesia -ASA classification* Surgery information -Type of surgery -Surgeon volume -Bleeding -Operation duration Complications -According to the ECCG -Clavien-Dindo classification Oncological treatment -Neoadjuvant and adjuvant treatment -Treatment modality -Complications Pathology -Tumour location and stage -Lymph node yield and resection radicality Hospital and ICU stay
<i>Biobanks</i>	Scans of original diagnostic slides

Supplementary Table 1. The diagnosis codes used to identify patients with esophageal and gastric cancer. The use of ICD-9 and ICD-10 overlapped, and therefore, both codes are used for searching for patients in 1995-1997.

	ICD-9 (before 1997)	ICD-10 (1995 and after)
Oesophageal cancer	150	C15
Gastric cardia cancer	151A	C16.0
Gastric cancer	151B - 151X	C16.1 - C16.9

Supplementary Table 2. The surgical codes used to identify patients undergoing surgical treatment for esophago-gastric cancer.

	THL Surgical Codes (1983-1996)	NOMESCO classification (1996 -)
Oesophageal resection	6201, 6202, 6203, 6204, 6205, 6209	JCC00, JCC10, JCC11, JCC12, JCC20, JCC30, JCC96, JCC97
Resection of the cardia	6301, 6320	Not applicable
Gastric resection:	6314, 6315, 6316, 6317, 6318, 6321, 6322, 6323, 6329	JDC00, JDC10, JDC11, JDC20, JDC30, JDC40, JDC96, JDC97, JDD00, JDD96
Endoscopic mucosal resection / Endoscopic submucosal dissection	Not applicable	JCA45, JCA52, JDA45, JDA52, JDH52

Supplementary Table 3. The definition of Charlson's comorbidity index.

The Charlson's comorbidity index will be calculated according to Armitage et al.¹ using hospital admissions up to 3 years before the index admission (surgery), and the index admission, and will exclude esophago-gastric malignancies.

Disease	ICD-10 codes
Myocardial infarction	I21*, I22*, I23*, I252
Congestive cardiac failure	I11, I13, I255, I42, I43, I50, I517
Peripheral vascular disease	I70–I73, I770, I771, K551, K558, K559, R02, Z958, Z959
Cerebrovascular disease	G45, G46, I60–I69
Dementia	A810, F00–F03, F051, G30, G31
Chronic pulmonary disease	I26, I27, J40–J45, J46*, J47, J60–J67, J684, J701, J703
Rheumatological disease	M05, M06, M09, M120, M315, M32–M36
Liver disease	B18, I85, I864, I982, K70, K71, K721, K729, K76, R162, Z944
Diabetes mellitus	E10–E14
Hemiplegia or paraplegia	G114, G81–G83
Renal disease	I12, I13, N01, N03, N05, N07, N08, N171*, N172*, N18, N19*, N25, Z49, Z940, Z992
Any malignancy	C00–C14, C17–C26, C30–C34, C37–C41, C43, C45–C58, C60–C76, C80–C85, C88, C90–C97
Metastatic solid tumour	C77–C79
AIDS/HIV infection	B20–B24

*Will be only taken into account for previous, not current, hospital admissions, because these are common complications after surgery and cause confounding to the comorbidity index.

References

1. Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity Consensus G. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. *Br J Surg* 2010;97(5):772-81. doi: 10.1002/bjs.6930

FINEGO clinical data collection form

Personal identification number:.....

1 Hospital:

2 Operation date:.....

3 Surgeon(s) 1:..... (First name, Surname)

2:

3:

4 Anesthesiologist(s): 1:..... (First name, Surname)

2:.....

3:.....

5 Operation codes:.....

6 Anesthesia codes:.....

7 Sex:

1. Man

2. Woman

8 Tumor localization

1. Upper 1/3 (upper border <25 cm from incisors)

2. Middle 1/3 (upper border 25-30 cm)

3. Lower 1/3 (upper border >30 cm)

4. Cardia, Siewert type 2 (center -1 - +2cm from Z line)

5. Cardia, Siewert type 3 (center 2-5cm below Z line)

6. Stomach body

7. Stomach distal

999 Not clear

9 Treatment determined in multidisciplinary meeting

0. No

1. Yes

10 Preop Treatment:

0. No

1. Yes

998. Not clear

11 Type of treatment:

1. Chemotherapy

2. Radiation

3. Radiation+Chemotherapy

12 Complications of neoadjuvant treatment

0. None, completed as planned

1. Yes, with delay/reduction, why _____

2. Yes, with termination, why _____

13 Preoperative lab

Value

Date

Not available

Hb:	_____	_____	_____
Alb:	_____	_____	_____
Prealb:	_____	_____	_____
CRP	_____	_____	_____
BMI	_____	_____	_____

14 ASA Class

15 Resection type:
(circle)

1. Transthoracic resection: a. Ivor-Lewis, b. McKeown
2. Transhiatal resection
3. Total gastrectomy
4. Proximal gastrectomy
5. Distal gastrectomy
6. Other _____

16 Intent of surgical approach

1. Open surgery
2. Hybrid thoroscopic
3. Hybrid laparoscopic
4. Totally minimally invasive (thoracoscopy + laparoscopy)
5. Totally laparoscopic (no thoracotomy/scopy)
5. Other _____

16.1 Only minimally invasive surgery: converted open?

0. No
1. Converted to hybrid
2. Yes

17 Lymphadenectomy

Esophagectomy

Gastrectomy

- | | |
|---|--|
| <ol style="list-style-type: none"> 1. 2-field 2. Extended 2-field 3. 3-field | <ol style="list-style-type: none"> 4. D0 lymphadenectomy 5. D1 lymphadenectomy 6. D2 lymphadenectomy 7. D3 lymphadenectomy 999. Unclear |
|---|--|

18 Tumor length: mm

19 Substitute:

1. Stomach
2. Small intestine
3. Colon

20 Type of anastomosis:

1. Handsewn:
2. Staples

21 Location of anastomosis:

1. Neck
2. Thorax
3. Abdomen

22 Splenectomy:

1. Yes: why?
2. No

23 Use of energy devices

1. Bipolar (LigaSure)
2. Ultrascision (Harmonic),
3. Hybrid (Thunderbeat)
4. Other
5. No

24 Fundoplication:

1. Before surgery: type?
2. During surgery: type?
3. No

25 Frozen section (circle all that apply):

- | | |
|------------------------------|----------------|
| 1. Distal resection margin | 4. None |
| 2. Proximal resection margin | 998. Not clear |
| 3. Lymph node | |

26 Jejunio-cath (feeding enterostomy):

1. Yes
2. No

27 Curative intended treatment:

1. Yes
2. No (palliative resection)
3. Rescue surgery (after curative chemoradiation)
998. Not clear

28 Duration of surgery: min (surgery start-stop)**29 Peroperative bleeding..... ml**

For the following, count only midnights; morning Wednesday to evening Thursday = 1

30 Days at the ICU**31 Days in respirator:****32 Days in hospital:****33 Further treatment in:**

1. Home
2. Health care center (terveyskeskus)
3. Another hospital
4. Rehabilitation center
5. Other _____

34 Complications in 90 days after operation:

1. No
2. Yes (fill in pages 6-10)

35 Reoperations in 90 days after operation:

1. No
2. Yes (fill in pages 6-10)

36 Adjuvant treatment

- 1.No
2. Chemotherapy
3. Radiotherapy

37 Adjuvant treatment status

1. Completed without complications
2. Complications: _____
3. Not completed, why? _____

1 **38 Proximal resection margin: mm**

2
3 **39 Distal resection margin: mm**

4
5 **40 Circumferential resection margin: mm**

6
7 **41 Histology:**

- 8 1. Adenocarcinoma
- 9 2. Squamous cell carcinoma
- 10 3. High-grade dysplasia
- 11 4. Low-grade dysplasia
- 12 5. Other _____
- 13 999 Not clear

14
15
16 **41.1 Laurén class:**

- 17 1. Diffuse
- 18 2. Intestinal
- 19 3. Indeterminate
- 20 999. Unavailable

16 **41.2 WHO histology classification (gastric cancer)**

- 17 1. Papillary
- 18 2. Tubular
- 19 3. Mucinous
- 20 4. Signet ring / poorly cohesive
- 21 5. Other types, which _____
- 22 999. Unavailable

23
24
25
26 **42 Preoperative stage (before any treatment)**

27 **T:**

- 28 1 Tis
- 29 2 T1 – T3
- 30 3 T1
- 31 4 T2
- 32 5 T3
- 33 6 T4
- 34 7 Tx
- 35 8 T0

36
37 **43 N:**

- 38 1 N0
- 39 2 N1
- 40 3 N2
- 41 4 N3
- 42 999 not clear

43
44 **44 M:**

- 45 0 M0
- 46 1 MIa
- 47 2 MIb
- 48 999 Not Clear

45 Postoperative stage (According to PAD or patient records)

T:

- 1 Tis
- 2 T1 – T3
- 3 T1
- 4 T2
- 5 T3
- 6 T4
- 7 Tx
- 8 T0

46 N:

- 1 N0
- 2 N1
- 3 N2
- 4 N3
- 999 not clear

47 Lymph nodes with metastasis: pcs

48 Number of Lymph nodes examined:..... pcs

49 M:

- 0 M0
- 1 MIa
- 2 MIb
- 999 Not Clear

50 G/Differentiation:

1. G1, well differentiated
2. G2, moderately differentiated
3. G3, poorly differentiated
4. GX, cannot be assessed

51 Tumor stage:

- 0 0 (pat only op)
- 1 I
- 2 IIA
- 3 IIB
- 4 III
- 5 IV
- 6 IVA
- 7 IVB
- 8 No cancer/dysplasia
- 9 Complete response after neo
- 999 not clear

52 Micr radically:

0 No	54 R0/R1/R2	1 R0
1 Yes		2 R1
999 Not clear		3 R2
		999 not clear

53 Macr radically:

- 0 No
- 1 Yes
- 999 Not Clear

55 Becker regression grade:

1. No tumor left (1a)	4. >50% tumor left (3)
2. <10% tumor left (1b)	
3. <10-50% tumor left (2)	999. Not applicable

COMPLICATIONS

56 Complications during 30 days after surgery (circle) and 30-90 days after surgery (square)
-Mark the main categories and all sub-categories that apply!

1. Pulmonary complications
 - a. Pneumonia
 - b. Pleural effusion requiring additional drainage procedure
 - c. Pneumothorax requiring treatment
 - d. Atelectasis mucous plugging requiring bronchoscopy
 - e. Respiratory failure requiring intubation
 - f. Acute respiratory distress syndrome (ARDS)
 - g. Acute aspiration
 - h. Tracheobronchial injury
 - i. Chest tube for air leak over 10 days postop

2. Cardiac complications
 - a. Cardiac arrest requiring CPR
 - b. Myocardial infarction (Troponin + ECG)
 - c. Atrial dysrhythmia requiring treatment
 - d. Ventricular dysrhythmia requiring treatment
 - e. Congestive heart failure requiring treatment
 - f. Pericarditis requiring treatment

- 1 3. Gastrointestinal complications
- 2
- 3 a. Esophagoenteric leak from anastomosis or conduit necrosis
- 4
- 5 i. Type 1: local defect requiring no change in therapy, treated medically or diet
- 6
- 7 ii. Type 2: requiring intervention, no surgery (radiology, stent, bedside opening)
- 8
- 9 iii. Type 3: Defect requiring surgery
- 10
- 11
- 12 b. Conduit necrosis/failure
- 13
- 14 i. Type 1: Focal conduit necrosis identified endoscopically, causes additional
- 15 monitoring or non-surgical therapy
- 16
- 17 ii. Type 2: Focal conduit necrosis, treated by surgical therapy but not diversion
- 18
- 19 iii. Type 3: Conduit necrosis requiring conduit resection and diversion
- 20
- 21
- 22
- 23 c. Ileus preventing or delaying enteral feeding
- 24
- 25 d. Small bowel obstruction
- 26
- 27 e. Feeding J-tube complication
- 28
- 29 f. Pyloromyotomy/pyloroplasty complication
- 30
- 31 g. Clostridium infection
- 32
- 33 h. GI bleeding requiring intervention or transfusion
- 34
- 35 i. Delayed conduit emptying requiring intervention or delaying discharge, or requiring
- 36 nasogastric tube >7 days
- 37
- 38
- 39
- 40
- 41 j. Pancreatitis
- 42
- 43 k. Pancreatic fistula
- 44
- 45 l. Liver dysfunction
- 46
- 47 m. Biliary leakage
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1 4. Urologic
- 2
- 3 a. Acute renal failure (doubling of baseline creatinine)
- 4
- 5 b. Acute renal failure requiring dialysis
- 6
- 7 c. Urinary tract infection
- 8
- 9
- 10 d. Urinary retention requiring re-insertion of catheter, delaying discharge, or discharge with
- 11 catheter
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19 5. Thromboembolic
- 20
- 21 a. DVT (ultrasound or angio verified)
- 22
- 23 b. Pulmonary embolism
- 24
- 25 c. Stroke (defined by CT or similar)
- 26
- 27
- 28 d. Peripheral thrombophlebitis (clinically verified)
- 29
- 30
- 31
- 32
- 33
- 34
- 35 6. Neurologic / psychiatric
- 36
- 37 a. Recurrent nerve paresis (mark: A unilateral, B bilateral)
- 38
- 39
- 40 i. Type 1: Transient injury, requires no other therapy than dietary modification
- 41
- 42 ii. Type 2: Injury requiring elective surgery (thyroplasty or medialization
- 43 procedure)
- 44
- 45
- 46 iii. Type 3: Injury requiring acute surgery due to aspiration or respiratory issues
- 47
- 48
- 49 b. Other neurologic injury
- 50
- 51 c. Acute delirium
- 52
- 53
- 54 d. Delirium tremens (alcohol withdrawal symptom)
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7. Infection
 - a. Wound infection requiring opening wound or antibiotics
 - b. Central line infection requiring removal or antibiotics
 - c. Intra-abdominal abscess
 - d. Intrathoracic abscess
 - e. Sepsis
 - f. Other infection requiring antibiotics, what
 8. Wound/diaphragm
 - a. Thoracic wound dehiscence
 - b. Acute abdominal wall dehiscence / hernia
 - c. Acute diaphragmatic hernia
 9. Other
 - a. Chyle leak (Mark: A. <1 liter per day, B >1 liter per day)
 - i. Type 1: requires dietary modifications, but not totally parenteral nutrition
 - ii. Type 2: requires totally parenteral nutrition
 - iii. Type 3: requires surgery or other intervention (chest drains not included)
 - b. Reoperation for reason other than bleeding, anastomotic leak or conduit necrosis, reason.....
 - c. Multiple organ failure

57 Clavien-Dindo classification for complications (only the most severe grade to be ticked)

0. No complications
1. Grade 1 (Any deviation from postoperative course, including antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy or opening the wound bedside)*
2. Grade 2 (Blood transfusion, total parenteral nutrition or pharmacological treatment needed other than I)
3. Grade 3 (Surgical, endoscopic or radiological intervention)
4. Grade 4 (Life-threatening complications requiring IC/ICU-management, or stroke (not TIA) or any brain hemorrhage)
5. Grade 5 (Death of a patient)

58 REOPERATIONS**Reoperation 1**

Days from primary operation: _____

Reason for operation: _____

Result: _____

Reoperation 2

Days from primary operation: _____

Reason for operation: _____

Result: _____

Reoperation 3

Days from primary operation: _____

Reason for operation: _____

Result: _____